An unrivalled concentration of biopharmaceutical ecosystems. Multiple world-class universities. A long history of strategic partnerships between science, industry and government. All this explains why The Netherlands is a perfect location for biopharmaceutical innovation in Europe.
The Netherlands is well-known for its top-notch infrastructure for clinical research. There are twelve universities engaged in biomedical research, and seven University Medical Centers. Together, they maintain an excellent track record in the fields of cardiovascular-, infectious- and neurogenerative diseases and cancer research.
Many innovative LSH companies establish themselves in The Netherlands. Its reputation as a strategic location was solidified when the European Medicine Agency (EMA) decided to move from London to Amsterdam in 2019.
There are more than 400 biopharmaceutical companies, all within a 120-mile radius together with the universities and UMCs. With this proximity, the open culture, the multilingual workforce and the world’s highest amount of public-private partnerships, The Netherlands offers the right climate for businesses to flourish.